Evidence map›Paper›PMID 40622568›Full record

ArticleNeuroradiology2025

Predictors of residual and recurrent pituitary neuroendocrine tumors: impact of medial cavernous sinus wall invasion and Trouillas grading.

Rosalinda Calandrelli, Fabio Pilato, Gabriella D'Apolito, Diletta De Lucia, Sabrina Chiloiro, Marco Gessi, Pierpaolo Mattogno, Liverana Lauretti, Francesco Doglietto, Simona Gaudino

Abstract read
PubMed Publisher
In one paragraph

Article in Neuroradiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Rosalinda CalandrelliRadiology and Neuroradiology Unit, Department of Imaging, Radiation Therapy and Hematology, Università Cattolica del Sacro Cuore, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Largo A. Gemelli, 1, Rome, 00168, Italy. rosalinda.calandrelli@policlinicogemelli.it.ORCID http://orcid.org/0000-0003-4517-3477
Fabio PilatoUnit of Neurology, Neurophysiology, Neurobiology, Università Campus Bio-Medico, Fondazione Policlinico Universitario Campus Bio-Medico, Via Alvaro del Portillo, Rome, Italy.
Gabriella D'ApolitoRadiology and Neuroradiology Unit, Department of Imaging, Radiation Therapy and Hematology, Università Cattolica del Sacro Cuore, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Largo A. Gemelli, 1, Rome, 00168, Italy.
Diletta De LuciaRadiology and Neuroradiology Unit, Department of Imaging, Radiation Therapy and Hematology, Università Cattolica del Sacro Cuore, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Largo A. Gemelli, 1, Rome, 00168, Italy.
Sabrina ChiloiroDepartment of Endocrinology, Pituitary Unit, Fondazione Policlinico Universitario Agostino Gemelli, IRCCS, Largo A. Gemelli, 8, Roma, 00168, Italy.
Marco GessiDepartment of Woman and Child Health Sciences and Public Health, Anatomic Pathology Unit, Fondazione Policlinico Universitario A. Gemelli- IRCCS, Largo A. Gemelli, 8, Roma, 00168, Italy.
Pierpaolo MattognoNeurosurgery Unit, Fondazione Policlinico Universitario Agostino Gemelli, IRCCS, Largo A. Gemelli, 8, Roma, 00168, Italy.
Liverana LaurettiNeurosurgery Unit, Fondazione Policlinico Universitario Agostino Gemelli, IRCCS, Largo A. Gemelli, 8, Roma, 00168, Italy.
Francesco DogliettoNeurosurgery Unit, Fondazione Policlinico Universitario Agostino Gemelli, IRCCS, Largo A. Gemelli, 8, Roma, 00168, Italy.
Simona GaudinoRadiology and Neuroradiology Unit, Department of Imaging, Radiation Therapy and Hematology, Università Cattolica del Sacro Cuore, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Largo A. Gemelli, 1, Rome, 00168, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeTo identify the histopathological and radiological variables that can predict tumor persistence and recurrence at follow-up in Pituitary neuroendocrine tumors (PitNets) classified by Trouillas’ grading system.

methodsA total of 187 PitNets with medium (Knosp grades 2 and 3 A) and high risk (Knosp grades 3B and 4) for medial wall of the cavernous sinus (MWCS) invasiveness were classified according to the Trouillas’ score. The predictive value of Trouillas’ final grading system, along with radiological (lobulated configuration, tumor volume, T2 signal intensity values) and surgical/histopathological variables (invasiveness, proliferative status) was evaluated for forecasting tumor persistence and recurrence.

resultsDiscrepancies between surgical MWCS invasiveness and Knosp grades 2, 3 A, and 3B emerged within Trouillas grades 2a and 2b. Post-surgery, residual tumors were found in 91 out of 187 cases, predominantly near cavernous sinuses and in Trouillas grades 1b, 2a, and 2b. During follow-up, 40 cases had stable residue, while 52 cases exhibited recurrence, more frequently in Trouillas grades 2a and 2b. Residual and recurrent tumor prediction emerged by separating the Trouillas grades into invasive and non-invasive. MWCS invasiveness (p = 0.031), lobulated tumor configuration (p = 0.044), and low nT2min values (< 0.001) were the primary predictors of residual tumor; whereas only MWCS invasiveness (p = 0.008) predicted tumor recurrence.

conclusionIn PitNets, MWCS invasiveness remains the foremost independent prognostic factor for both residual tumor and recurrence.

Indexed as

Cavernous SinusMagnetic Resonance ImagingNeoplasm Recurrence, LocalNeuroendocrine TumorsPituitary NeoplasmsFemaleHumansMaleNeoplasm GradingNeoplasm InvasivenessNeoplasm, ResidualPredictive Value of TestsRetrospective StudiesMagnetic resonance imagingMedial wall invasiveness of the cavernous sinusPitNetTrouillas grading system

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.